PF-08046876 / Pfizer - LARVOL DELTA

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=540 | Recruiting | Sponsor: Pfizer | N=310 ➔ 540

Enrollment change • Bladder Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

PF-08046876, a differentiated integrin beta-6 antibody-drug conjugate delivering a potent camptothecin payload optimized for bystander effect and reduced drug efflux. (PubMed, Mol Cancer Ther) - "PF-08046876 leverages the same antibody backbone from sigvotatug vedotin (SV) and binds IB6 without cross-reactivity to other alpha-v integrin complexes. In preclinical studies, PF-08046876 has demonstrated significant antitumor activity both in vitro and in vivo across multiple tumor models with IB6 expression, including non-small cell lung (NSCLC), head and neck squamous cell (HNSCC), urothelial (UC), pancreatic (PDAC), and esophageal (ESCA) carcinomas. These findings support further clinical development of PF-08046876 as a promising therapeutic candidate for the treatment of IB6-expressing solid tumors."

Journal • Esophageal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • TOP1

PF-08046876: A new camptothecin antibody-drug conjugate directed to integrin beta-6 with potent antitumor activity in multiple preclinical solid tumor models (AACR 2025) - "PF-08046876 leverages the same antibody backbone from Sigvotatug Vedotin (SV) and is specific for IB6 but does not bind other alpha-v family members. These results suggest that PF-08046876 is promising ADC for the treatment of multiple carcinomas and supports further clinical investigation. A Phase 1, first-in-human study is planned to evaluate the safety and anti-tumor activity of PF-08046876."

ADC • First-in-human • Preclinical • Cervical Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • TOP1

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=310 | Recruiting | Sponsor: Pfizer

Trial initiation date • Bladder Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

C5951001- A Phase 1 Study of PF-08046876 in Participants with Advanced Solid Tumors. (clinicaltrialsregister.eu) - P1 | N=70 | Not yet recruiting | Sponsor: Pfizer Inc.

New P1 trial • Oncology • Solid Tumor

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=310 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Bladder Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=310 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Bladder Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer